As GLP-1 Drugs Change How People Eat, Drugmakers Collect and Snack Makers Feel the Squeeze

GLP-1 weight-loss drugs like Wegovy and Zepbound are rapidly gaining adoption, with 11% of U.S. adults now using them. This is benefiting drug manufacturers Eli Lilly and Novo Nordisk, whose sales are surging. However, snack and beverage companies face headwinds as GLP-1 users reduce grocery spending by 5-8%, particularly on processed snacks. While some companies like Coca-Cola and Monster Beverage are weathering the impact due to their low-calorie portfolios, others like PepsiCo and Hershey are experiencing declining sales.